EP Patent

EP4681702A1 — Oral solution comprising vortioxetine hydrobromide

Assigned to Pharmapath SA · Expires 2026-01-21 · 0y expired

What this patent protects

An oral pharmaceutical solution comprising vortioxetine hydrobromide and a pharmaceutically acceptable aqueous carrier comprising hydroxypropylbetadex and a cosolvent system consisting of a mixture of ethanol and glycerol, wherein the pH of the solution is from 4.5 to 6.5.

USPTO Abstract

An oral pharmaceutical solution comprising vortioxetine hydrobromide and a pharmaceutically acceptable aqueous carrier comprising hydroxypropylbetadex and a cosolvent system consisting of a mixture of ethanol and glycerol, wherein the pH of the solution is from 4.5 to 6.5.

Drugs covered by this patent

Patent Metadata

Patent number
EP4681702A1
Jurisdiction
EP
Classification
—
Expires
2026-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Pharmapath SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.